Select Language
Free Registration

HLA-A*0201 & B2M & HPV (TIHDIILECV)

HLA-A*0201 & B2M & HPV (TIHDIILECV) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Avi Tag (1)

  • Conjugate

    Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HLV-H82E5
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&HPV (TIHDIILECV) Complex Protein (Monomer, MALS verified)
Total: 1
  • 1

HLA-A*0201 & B2M & HPV (TIHDIILECV) Background

Human papillomavirus (HPV) is A kind of papillomavirus belonging to the milk polypoid virus family. It is a spherical D virus, which can cause the proliferation of squamous epithelium of human skin mucosa. HPV(human papillomavirus) for common warts, genital warts (condyloma acuminatum), and other symptoms. There are many types of human papillomavirus (HPV), with HPV 16 and 18 being high-risk types known to significantly increase the risk of cervical, vaginal and vulvar cancers in women and men. The Biotin human HLA-A*0201 HPV (TIHDIILECV) protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and TIHDIILECV peptide of the HPV.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Ningetinib TosylateCT-053-PTSA; CT-053Phase 2 ClinicalHec Pharm Co LtdIntestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung
Details
Do-2Do-2Phase 1 ClinicalDeuterOncology NVLung Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
CrizotinibPF-1066; PF-2341066; PF-02341066; PF-002341066ApprovedPfizer Inc赛可瑞, XalkoriUnited StatesCarcinoma, Non-Small-Cell LungPf Prism Cv2011-08-26Urethral Neoplasms; Neoplasm Metastasis; Adenocarcinoma; Neurilemmoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Granuloma, Plasma Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Ureteral Neoplasms; Solid tumours; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Neuroblastoma; Urinary Bladder Neoplasms; Myofibroma; Uveal melanoma; Multiple Myeloma; Neurofibromatosis 2; Neoplasms; Renal Insufficiency; Hematologic Neoplasms
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland